$PRVB 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

CEO

Ashleigh Palmer

Exchange

NASDAQ

Website

www.proventionbio.com

$M

Total Revenue

59

Employees

$400M

Market Capitalization

-3.12

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 19327 2239 2.87 15.52 43.40
Organon & Co. OGN 8644 7891 -4.46 4.95 22.06
Arvinas Inc ARVN 4342 21 8.14 -26.29 -782.93
Tilray Inc TLRY 3286 513 1.23 -9.74 -71.61
ATAI Life Sciences N.V. ATAI 2545 20 5.35 -11.65 -932.88
Cronos Group Inc CRON 2114 57 1.33 -14.64 -258.59
Usana Health Sciences Inc USNA 1837 1254 4.18 13.23 11.09
Phathom Pharmaceuticals Inc PHAT 1178 7.99 -7.35 None
Fulcrum Therapeutics Inc FULC 925 15 11.21 -12.53 -481.07
Intersect ENT Inc XENT 899 103 21.80 -13.10 -66.55
Phibro Animal Health Corp. PAHC 888 833 3.68 16.16 6.53
Edgewise Therapeutics Inc EWTX 848 2.87 -31.45 None
Pliant Therapeutics Inc PLRX 657 13 2.69 -7.66 -613.56
Cyteir Therapeutics Inc CYT 637 3.42 -22.04 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 467 10 2.52 -8.53 -551.28
Chromadex Corp CDXC 433 62 10.92 -18.30 -37.51
Rain Therapeutics Inc RAIN 404 413 2.50 -13.27 123.20
Provention Bio Inc PRVB 400 2.68 -3.12 None
Evolus Inc EOLS 321 77 4.24 -2.15 -171.53
Verrica Pharmaceuticals Inc VRCA 316 12 6.41 -8.69 -301.45
Terns Pharmaceuticals Inc TERN 263 1.46 -7.62 None
Adicet Bio Inc ACET 230 9 1.00 -4.09 -603.06
Milestone Pharmaceuticals Inc MIST 222 15 1.25 -7.50 -215.93
Kaleido Biosciences Inc KLDO 222 1 4.94 -2.49 None
LifeMD Inc LFMD 201 64 -28.62 -1.44 -133.55
Kala Pharmaceuticals Inc KALA 187 11 2.42 -1.48 None
Osmotica Pharmaceuticals Plc OSMT 181 190 2.64 -1.95 -47.85
Citius Pharmaceuticals Inc CTXR 177 2.21 -7.70 None
scPharmaceuticals Inc SCPH 162 119 2.38 -5.36 -27.05
Aquestive Therapeutics Inc AQST 146 42 -3.02 -2.27 -152.73
Eton Pharmaceuticals Inc ETON 123 15 6.11 -10.06 -74.52
Odonate Therapeutics Inc ODT 117 1.47 -1.00 None
Eyenovia Inc EYEN 113 6 12.86 -5.77 -324.94
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Opiant Pharmaceuticals Inc OPNT 90 37 2.71 -86.08 -3.06
Natural Alternatives Internati NAII 89 169 1.26 10.07 5.68
VYNE Therapeutics Inc VYNE 72 16 1.08 3.27 -554.66
India Globalization Capital In IGC 67 0 2.39 -7.65 -981.18
Mannatech Inc MTEX 66 158 2.63 10.35 4.22
Acasti Pharma Inc ACST 42 0 1.81 -2.11 -611.47
Shineco Inc TYHT 36 14 1.85 -1.78 -159.60
Assertio Holdings Inc ASRT 33 117 0.45 -0.58 -38.05
Reviva Pharmaceuticals Holding RVPH 30 1.64 -4.74 None
Baudax Bio Inc BXRX 28 1 -11.98 0.84 None
Nabriva Therapeutics Plc NBRV 28 12 0.83 -0.47 -452.55
Bio-Path Holdings Inc BPTH 28 0 1.29 -2.68 18.96
Timber Pharmaceuticals Inc TMBR 26 0 11.39 0.88 -527.55
Trevi Therapeutics Inc TRVI 26 1.67 -0.74 None
Lexaria Bioscience Corp LEXX 25 1 3.49 -6.45 -445.15
Hoth Therapeutics Inc HOTH 22 1.85 -2.29 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.13 -2.04 -31.96

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

1d ago, source: YAHOO!Finance

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat ...

Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: PRVB) shares

2d ago, source: openpr.com

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Provention Bio, Inc.. Investors who are current long term investors in ...

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

4d ago, source: WFMZ-TV

RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status ...

Provention will wait for FDA to 'opine' on new data after teplizumab rejection, eyes Q4 for further talks

4d ago, source: FierceBiotech

Provention Bio is being optimistic about the chances of resubmitting the rejected Type 1 diabetes asset teplizumab after the ...

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

1d ago, source: Stockhouse

RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that ...

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

4d ago, source: PR Newswire

About Provention Bio, Inc.: Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent ...

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

1d ago, source: WFMZ-TV

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D.

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

4d ago, source: Benzinga.com

RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an ...

BRIEF-Provention Bio Provides Update On The Potential Timing Of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

4d ago, source: Reuters on MSN.com

PROVENTION BIO PROVIDES UPDATE ON THE POTENTIAL TIMING OF TEPLIZUMAB AT-RISK TYPE 1 DIABETES (T1D) BIOLOGICS LICENSE APPLICATION (BLA) RESUBMISSION * PROVENTION BIO INC - DATA COLLECTION COMPLETED FOR ...

Your Portfolio